In chronic kidney disease (CKD), multiple factors contribute to the development of cardiac hypertrophy by directly targeting the heart or indirectly by inducing systemic changes such as hypertension, anemia, and inflammation. Furthermore, disturbances in phosphate metabolism have been identified as nonclassical risk factors for cardiovascular mortality in these patients. With declining kidney function, the physiologic regulators of phosphate homeostasis undergo changes in their activity as well as their circulating levels, thus potentially contributing to cardiac hypertrophy once they are out of balance. Recently, two of these phosphate regulators, fibroblast growth factor 23 (FGF23) and Klotho, have been shown to affect cardiac remodeling, thereby unveiling a novel pathomechanism of cardiac hypertrophy in CKD. Here we discuss the potential direct versus indirect effects of FGF23 and the soluble form of Klotho on the heart, and their crosstalk in the regulation of cardiac hypertrophy.
INTRODUCTION
The interrelation between reduced renal function and altered cardiac remodeling in patients with chronic kidney disease (CKD) is termed uremic cardiomyopathy. In CKD, cardiac hypertrophy is the most commonly diagnosed cardiovascular abnormality and the strongest independent predictor of cardiovascular mortality [1] [2] [3] [4] [5] . The pathogenesis of uremic cardiomyopathy and underlying molecular pathways remain uncertain, and existing treatments improve outcomes only modestly [6] [7] [8] . Although there is a high prevalence of conventional cardiovascular risk factors in the CKD population, such as hypertension, diabetes, obesity, and lipid abnormalities, the relationship between these factors and outcome is less clear than in the general population [9, 10] . Recent studies suggest that circulating molecules, including uremic toxins such as indoxyl sulfate, may directly target the myocardium and initiate hypertrophic growth of cardiac myocytes independently of mechanical stress [11, 12] . Furthermore, disturbances of mineral metabolism, including hyperphosphatemia, secondary hyperparathyroidism, and vitamin D deficiency, have been identified as nonclassical risk factors for cardiovascular mortality in patients with CKD [13] [14] [15] [16] [17] . This review article focuses on two circulating factors that are involved in the regulation of phosphate homeostasis and that are misregulated in CKD -namely fibroblast growth factor 23 (FGF23) and Klothoand their potential direct effects on the heart that Produced by osteocytes, FGF23 is a hormone that regulates phosphate and vitamin D metabolism [18, 19] . In the kidney and parathyroids, the classic target organs of FGF23, the hormone binds FGF receptor (FGFR)/Klotho co-receptor complexes [20, 21] to stimulate phosphate excretion, inhibit parathyroid hormone secretion, and decrease levels of active vitamin D [22] [23] [24] [25] [26] . In patients with CKD, disordered phosphate metabolism occurs as a result of a defect in renal excretory capacity. Beginning in the early stages of CKD, serum FGF23 levels rise progressively as kidney function declines [27] , reaching levels 1000-fold above normal in advanced renal failure [28] . Although this massive increase in FGF23 helps to maintain normal serum phosphate levels [29] , prospective human studies demonstrated a dose-dependent association between FGF23 levels, increased prevalence of cardiovascular disease and greater risk of mortality among CKD patients [30] [31] [32] [33] [34] . A potential mechanism linking FGF23 to cardiovascular disease is its strong association with cardiac hypertrophy [30, 33, [35] [36] [37] [38] .
Several studies have shown that rodent models with elevated serum FGF23 levels develop cardiac hypertrophy [38,39 & ,40]. Since the experimental increase of FGF23 concentrations by injection of recombinant FGF23, application of a high phosphate diet, or induction of a CKD phenotype via renal ablation, adenine diet, or Klotho deletion result in many other systemic effects, it would be important to also conduct these studies in animals lacking FGF23 in order to determine a causative interrelation between FGF23 and cardiac hypertrophy. However, ,46], indicating that the FGF23/ FGFR4/PLCg/calcineurin/NFAT signaling axis is a major inducer of cardiac hypertrophy in rodents with high serum FGF23 levels. Interestingly, these treatments in rats do not reduce blood pressure or improve kidney function, indicating that hypertension or other factors altered by kidney injury are not major drivers of cardiac hypertrophy in this particular animal model of CKD.
KEY POINTS
FGF23 elevations in mice with cell type-specific FGFR4 gene deletion will be necessary to confirm that FGFR4 in cardiac myocytes is required for the development of cardiac hypertrophy, which would also provide further evidence that indeed FGF23 can directly target cardiac myocytes in the rodent heart, as strongly suggested by the existing in-vitro data derived from cardiac myocyte cultures [38,43,44 & ]. Constant infusions of FGF23 using osmotic minipumps are necessary to precisely characterize the cardiac effects of FGF23 in a time-dependent and dose-dependent manner, and to determine if FGF23 elevations can eventually lead to heart failure. Furthermore, it needs to be investigated if FGF23, possibly after short or lowdose exposure, has beneficial effects on cardiac structure and function, as suggested by a study in isolated adult cardiac myocytes and ventricular muscle strips from mice reporting increased contractility following FGF23 treatment [43] .
Combined, these experimental studies provide strong evidence that elevated FGF23 is a causal factor in the pathogenesis of uremic cardiomyopathy, thereby repositioning FGF23 from biomarker of risk to mechanism of cardiac injury in CKD ( Fig. 2a ). Human studies, although not capable of providing direct evidence for causality, support the existence of such an FGF23-driven pathomechanism in the heart. First, a recent retrospective study showed that in children with end-stage renal disease, FGFR4 expression levels and calcineurin/NFAT activity in the heart associate with cardiac hyper- trophy ]. Fourth, serum FGF23 levels associate with cardiac hypertrophy in cardiovascular cohorts with no or only slightly impaired renal function [51] [52] [53] [54] [55] [56] . A recent study in a mouse model for myocardial infarct confirmed an association between primary cardiac injury and elevated serum FGF23 levels [57 & ]. It is possible that in this scenario an unknown endocrine heart-bone feedback mechanism elevates FGF23 synthesis and secretion in bone [56,57 & ]. In contrast, other studies suggest that FGF23 does not directly harm the heart, but rather that other factors that correlate with FGF23 elevations in CKD cause cardiac hypertrophy [58] [59] [60] . First, pharmacologic FGF23 blockade does not reduce cardiac hypertrophy in 5/6 nephrectomized rats [42] . The outcome of this study seems to be contradictory to the observed antihypertrophic effects of FGF23 receptor blockade [38,44 & ]. Although the respective studies used the same surgical rat model of CKD, they also exhibited important differences in other experimental parameters, such as normal versus high phosphate diet, start of pharmacological intervention at 1 hour versus 4 weeks post surgery, and analysis of cardiac alterations at 2 versus 8 weeks after surgery. Therefore, it is impossible to directly compare the outcome of these studies. Furthermore as discussed above, FGF23 blockade by itself is detrimental as it induces cardiovascular injury and decreases survival in rodents [41, 42] . Second, although administration of the phosphate binder sevelamer in a mouse model of CKD lowered serum FGF23 levels and prevented progression of cardiac hypertrophy, a multiple regression analysis revealed that only serum phosphate, but not serum FGF23, independently correlated with left ventricular mass [61] , indicating that phosphate's calcifying effects on the vasculature rather than FGF23 effects on the heart are responsible for the observed cardiac hypertrophy in this particular animal model. Moreover in a human CKD study, sevelamer reduced serum FGF23 levels but did not significantly reduce cardiac hypertrophy or improve cardiac function [62] . Third, by directly targeting distal tubules, FGF23 regulates renal sodium handling and elevates blood pressure, and FGF23's hypertensive effect seems to be required for the development of cardiac hypertrophy in mice [50 & ]. Other studies have indicated that FGF23 might activate the rennin-angiotensin system and elevate blood pressure [63] , but detailed analyses are necessary to reveal the underlying molecular mechanism.
Overall, the molecular mechanisms by which FGF23 affects cardiac structure and function are not fully understood. As in human CKD studies, association analyses in animal models of CKD do not provide evidence to distinguish between direct versus indirect effects, and they will not help to provide novel insights into the causality of events [39 & ,61] . Instead, animal models such as gene knockout and knockin in mice should be used to study protein function in a tissue-specific manner in order to determine the contribution of a particular protein to a specific type of tissue injury, such as cardiac hypertrophy. In recent years, the reported number of cell types that are able to directly respond to FGF23 has been growing. Therefore, it is likely that in addition to its direct cardiac effects, systemic changes induced by FGF23, such as hypertension [50 & ] or inflammation [64] , contribute to cardiac injury, suggesting that high serum FGF23 levels, as found in CKD, can hit the heart in several ways that might act synergistically.
Cardiac effects of Klotho
Klotho is a single-pass transmembrane protein that is expressed in several organs, including the kidney [20] . Klotho acts as a co-receptor for FGF23 and increases the affinity of FGF23 for FGFR binding [21, 65, 66] , thus mediating FGF23's physiologic effects in the regulation of phosphate homeostasis. CKD is a state of Klotho deficiency [67] [68] [69] , which can be due to a reduction in functional kidney mass and thereby a loss of Klotho expressing tubular epithelial cells. Furthermore, specific factors that are elevated in CKD can downregulate the expression of Klotho in the kidney, such as angiotensin II (AngII) [70] [71] [72] [73] , inflammatory cytokines [74] [75] [76] [77] , or phosphate [39 & ]. Vitamin D [78] [79] [80] and erythropoietin [81, 82] increase renal Klotho expression, and therefore vitamin D deficiency and anemia might contribute to a reduction in Klotho levels in CKD.
Mice lacking Klotho develop an aging and CKDlike phenotype including severe cardiovascular pathologies, such as vascular calcification as well as cardiac hypertrophy and fibrosis [20,38,39 & ,68] . It is currently under debate whether Klotho is expressed in the vasculature, and if a loss of membrane-bound Klotho in vascular smooth muscle cells or endothelial cells contributes to the calcification process [83, 84] . Since Klotho is not expressed in the heart [20, 38, 74] , a loss of membrane-bound Klotho cannot directly contribute to cardiac hypertrophy. Instead, cardiac effects of Klotho must be based on changes in Klotho expression or function, or both, in its classic organs, such as the kidney or parathyroids, leading to secondary changes in levels of systemic factors that can directly target the heart, such as phosphate or FGF23.
The extracellular domain of Klotho can also exist as a circulating form (i.e., soluble Klotho, or sKL) that can be generated on an mRNA level by alternative splicing or alternative transcriptional termination, or on a protein level by proteolytic cleavage of transmembranous full-length Klotho [85] [86] [87] [88] [89] [90] . The kidney appears to be the major source of sKL [91, 92] , and several different target cell types, such as endothelial cells and vascular smooth muscle cells, as well as a variety of cellular effects of sKL have been described. These functions seem to be exclusively beneficial and protective, including antioxidative, antiapoptotic, anti-inflammatory, antifibrotic, and antisenescence effects [93] [94] [95] [96] [97] [98] 99 & , [100] [101] [102] [103] . Several signal transduction pathways can be modulated by sKL thereby mediating its effects. These include the interference with the signaling of other paracrine and endocrine factors, such as insulin and insulin-like growth factor 1 (IGF1) [ [110] , and the modulation of intracellular signaling mediators, such as phosphoinositide 3-kinase (PI3K) [106] , b-catenin [111] , protein kinase A [97] , mitogen-activated protein kinase (MAPK) [95] , nuclear factor-kB (NFkB) [96, 102] , and calpain [112, 113] .
Based on the described findings, it has been postulated that sKL is a kidney-derived hormone with tissue-protective and anti-aging effects (Fig. 2b) . However, to date the sKL receptor has not been identified, and it remains unclear if sKL can directly activate signaling pathways and induce cellular effects in specific target cells. It has been shown that sKL can bind and inhibit TGFb type II receptor [109] and FGFR1 [103] , thereby competitively blocking fibrotic effects of TGFb and FGF2, respectively. Furthermore, sKL suppresses the activation of insulin/IGF1 receptor [88] , thereby blocking insulin and IGF1 signaling and contributing to anti-aging properties. However, it remains uncertain if sKL can directly bind these receptors. More detailed state-of-the-art binding analyses, including enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance spectroscopy, are required to determine specificity and affinity of these potential ligand-receptor interactions. The identification of the sKL receptor is challenging, and the mechanism might not necessarily be based on sKL binding to one particular receptor protein. Instead, it may involve sKL's activity as a deglycosylating enzyme [114, 115] that could affect several extracellular proteins or ectodomains of transmembrane proteins, thereby regulating cellular functions. To date, the hunt for the sKL receptor(s) is still ongoing, and its success will be key in order to move the concept of sKL as a humoral factor forward.
It has been shown in animal models and in patients with CKD that reduced renal expression of membrane-bound Klotho is accompanied by a decline in serum sKL levels [ Interestingly, recombinant sKL seems to be instable in uremic serum suggesting that decreased sKL production in the kidney may not be the sole reason for reduced serum sKL levels in CKD, and that increased sKL degradation in the circulation also contributes to sKL deficiency [116 & ]. Because in animal models of Klotho deficiency, restoration of Klotho expression and serum sKL levels ameliorates vascular calcification [68] and cardiac hypertrophy and fibrosis [39 & ,118 & ,119 & ], it has been hypothesized that the reduction of sKL's direct protective effects on the cardiovascular system causes injury [120, 121] .
Several experimental studies indicate that sKL might directly interfere with cardiac hypertrophy and fibrosis. The induction of hypertrophic growth of cardiac myocytes in culture and of cardiac hypertrophy and fibrosis in rodents via b-adrenergic activation can be blocked by sKL administration [106, [122] [123] [124] . In cultured cardiac myocytes, sKL inhibits AngII-induced, TGFb-induced and indoxyl sulfate-induced hypertrophy [39 & 
,119
& ], and suppresses apoptosis that has been induced by hypoxia/reoxygenation or by b-adrenergic stimulation [124, 125] . Furthermore, sKL attenuates AngII-mediated and TGFb-mediated activation of cultured cardiac fibroblasts [39 & ]. As in other tissues, cardiac sKL signaling seems to involve the blockade of IGF1, AngII, Wnt Mechanistically, sKL inhibits TRPC6, a calciumpermeable cation channel that is an important modulator of cardiac remodeling and an inducer of cardiac hypertrophy, by stimulating calciummediated signaling including the calcineurin/NFAT pathway [126] . Mice with cardiac-specific overexpression of TRPC6 spontaneously develop cardiac hypertrophy [126] . Elevation of circulating sKL levels in these mice prevents the development of cardiac hypertrophy and prolongs survival [106] . Furthermore, sKL inhibits TRPC6 cell surface expression and currents in cultured cardiac myocytes [106] , suggesting that sKL can directly target cardiac myocytes and mediates its antihypertrophic and cardio-protective effects by reducing TRPC6 activity and thereby calcineurin/NFAT signaling.
To date it remains unclear if sKL can directly target the heart. Since all models of Klotho deficiency involve a reduction of both forms, membrane-bound Klotho and sKL, it is impossible to distinguish between sKL's direct effects on the heart versus systemic changes mediated by membranebound Klotho. Blocking renal cleavage or release of sKL or specific inhibition of circulating sKL in healthy animals would help to clarify the situation.
It has been shown that administration of inhibitors for a-secretase and b-secretase, which modulate Klotho ectodomain shedding in the kidney [89, 90] , cause a reduction in serum sKL levels in mice [92] . However, potential cardiac effects of these inhibitors per se, or in the context of uremia, have not been reported. Furthermore, in order to experimentally determine if sKL can indeed directly target cardiac myocytes, it is inevitable that the receptor of sKL is identified and deleted in a cell type-specific manner in the mouse heart, as discussed above for the cardiac FGF23 receptor.
In contrast to the described clinical studies showing strong associations between FGF23 and cardiac hypertrophy in CKD and non-CKD populations, several human studies have failed to detect significant correlations between serum sKL levels, kidney function, cardiovascular disease, and survival in patients with CKD [127, 128] . Moreover, sKL levels do not associate with changes in cardiac mass or function or predict cardiovascular risk in cardiac patients with normal renal function [53, 129] . The later finding is supported by experimental myocardial infarct models in rats and mice, showing that serum levels of FGF23 but not of sKL are elevated [57 & ], indicating that at least in this particular type of primary cardiac injury FGF23 but not sKL might be causatively involved.
Of note, technical concerns hinder experimental and human studies and make data interpretation difficult. First, commercially available antibodies against Klotho, including the best-characterized antibody, termed KM2076 [130] , seem to be unspecific and cross-react with other proteins [84,116 & ]. Klotho ELISAs have provided inconstant results for serum sKL levels in CKD [116 & ]. A novel synthetic anti-Klotho antibody, termed sb106, has been shown to detect Klotho in tissue as well as sKL in serum and urine following an immunoprecipitation-immunoblot approach [92,116 & ]. However, this antibody is currently not commercially available. Second, the sKL protein seems to be highly unstable in blood, at least in the CKD milieu [92] , and in urine in general, even when urine samples were frozen [131] . Hence, prior analysis sKL degradation needs to be prevented to conserve sKL levels, but technical approaches to do so have not been described. Third, as sKL seems to be unstable, the generation of recombinant sKL for the treatment of cell cultures and for injections in animals is challenging. Since functional assays to monitor sKL activity are not available, it is currently impossible to determine if the applied sKL is indeed active, or if it underwent degradation most likely resulting in the loss or alteration of protein function.
Novel regulators of uremic cardiomyopathy Grabner and Faul
Potential crosstalk of fibroblast growth factor 23 and soluble Klotho in the regulation of cardiac remodeling Overall, these exciting new studies provide strong support for the hypothesis that FGF23 and sKL can directly affect cardiac remodeling. Since FGF23 and Klotho act as a ligand-receptor pair that is a key component for the regulation of phosphate homeostasis, it would be somewhat surprising if the cardiac actions of both proteins would be uncoupled and independent from each other. However, it remains challenging to experimentally determine direct pathologic contributions of low sKL versus high FGF23. In all known scenarios of Klotho deficiency, such as in primary deficiency, as in Klotho knockout or hypomorphic mice, as well as in secondary deficiency, as in CKD, aging, or phosphate loading, reduced serum sKL levels go hand in hand with elevated concentrations of circulating FGF23. Furthermore, the experimental increase in circulating sKL results in a reduction in serum FGF23 levels.
Because some of the important studies on cardiac sKL effects have not analyzed serum FGF23 levels [106,119 & ], and vice-versa studies focusing on direct cardiac actions of FGF23 have not analyzed sKL levels [38,44 & ], it remains difficult to compare both factors with regards to their direct causal involvement. Only a few experimental studies aimed to uncouple the reduction in sKL levels from the elevation of FGF23, followed by cardiac analyses. For example, it was reported that the normalization of serum levels of FGF23 and phosphate in CKD mice with heterozygous Klotho deletion does not abrogate cardiac hypertrophy [118 & ], suggesting that Klotho prevents uremic cardiomyopathy by mechanisms that are independent of FGF23 and phosphate, most likely by direct effects of sKL on cardiac myocytes. However, in this key experiment the heart was only analyzed by determining the ratio of heart weight to body weight, a vague measurement for cardiac hypertrophy, and levels of sKL and renal Klotho were also not reported. In addition, association studies in mice have shown that higher serum FGF23 levels only correlate with cardiac hypertrophy and fibrosis in concert with reduced sKL levels [39 & ], indicating that not high FGF23 but low sKL is the key contributor to uremic cardiomyopathy.
Can soluble Klotho act as a circulating receptor for fibroblast growth factor 23?
The role of the full-length Klotho protein is to mediate FGF23 interactions with target cells by enhancing FGF23's affinity for FGFR binding by over 20-fold [66] . Based on in-vitro analyses it has been questioned whether sKL can efficiently bind FGF23, and it has been concluded that circulating sKL exerts its effects independent of FGF23 [92] . First, in the presence of sKL, FGF23 can still activate MAPK signaling in HEK293 cells [65] . However, since dependent on the cell type and the presence of specific FGFR isoforms, FGF23 can stimulate different signal transduction pathways [132] , the analysis of MAPK signaling in generic cell lines might miss the detection of potential inhibitory actions of sKL on FGF23 effects. Second, surface plasmon resonance spectroscopy revealed that sKL binds FGF23 only poorly in the absence of FGFR [133] . However, since other factors such as serum proteins could affect the FGF23-sKL interaction, it needs to be experimentally determined if FGF23 and sKL can form a stable complex in the circulation. If true, such an interaction might most likely alter stability and half-life, as well as biological availability and function of both proteins. Interestingly, at the recent annual Kidney Week of the American Society of Nephrology, exciting data has been presented using highly specific antibodies against FGF23 and sKL in co-immunoprecipitation studies indicating that indeed both proteins can interact with each other in the circulation [134 && ]. If some of these newly developed antibodies could specifically block or strengthen the interaction between FGF23 and sKL, they would provide a valuable tool that could be used to experimentally determine the function of this interaction and to analyse the cardiac effects of both factors in a separate manner.
It is interesting to speculate that sKL can bind FGF23 thereby blocking Klotho-dependent and Klotho-independent effects in kidney and heart, respectively, and serving as a circulating decoy receptor for FGF23 ( Fig. 2c .I). However, experimental proof for such a hypothesis is still missing. A first step would be to determine if sKL can block FGF23-induced FGFR4/PLCg/calcineurin/NFAT signaling and hypertrophic growth in cultured cardiac myocytes. Interestingly, it has been shown that in myocardial tissue of CKD patients declining sKL protein levels in combination with elevated FGF23 production correlate with cardiac hypertrophy [47 & ]. This clinical finding indicates that a reduction in sKL's inhibitory actions towards FGF23's pro-hypertrophic effects might contribute to uremic cardiomyopathy, thereby supporting the hypothesis that sKL acts as a decoy receptor for FGF23.
Can soluble Klotho bind fibroblast growth factor receptors and act as a circulating co-receptor for fibroblast growth factor 23?
It has been shown in vitro that sKL can bind FGFRs [65] and increase the affinity of FGF23 for FGFR binding [133] . Therefore, it is possible that sKL acts as a circulating FGF23 co-receptor that can interact with membrane-bound FGFRs, thereby facilitating FGF23 binding to cell types that per se do not express Klotho and mediating temporary responsiveness to FGF23. Such a mechanism has been reported in fibroblast and myoblast cell lines in which the combined treatment with FGF23 and sKL activated FGFR1 and MAPK signaling leading to increased cell survival [135] . Furthermore, the transmembrane form of Klotho has been shown to modulate downstream signaling events [44 & ,136] . Therefore, in cell types that can respond to FGF23 in a Klotho-independent manner via FGFR4, such as cardiac myocytes, sKL binding might cause a switch in signaling pathways leading to different cellular effects of FGF23 ( Fig. 2c.II) .
CONCLUSION
FGF23 appears to function as a circulating factor that can directly target cardiac myocytes and induce cardiac hypertrophy independently of other stress factors [38,43,44 & ]. Furthermore, Klotho deficiency predisposes the heart to stress-induced cardiac hypertrophy [106,119 & ]. Thus, high FGF23 and low sKL may synergistically contribute to uremic cardiomyopathy by molecular mechanisms that are not completely understood. The theory that Klotho deficiency is deleterious whereas Klotho sufficiency is protective against pathologic effects of FGF23 might also explain other organ damage associated with CKD, as recently proposed for the endothelium [99 & ]. As CKD is a stage of both low sKL and high FGF23, and both trends aggravate with declining renal function, such a pathomechanism would serve as a plausible explanation for the dramatic increase in severity and extent of secondary organ injury, such as cardiac hypertrophy and fibrosis, as kidney injury progresses ( Fig. 3) .
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